Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib
Status:
Unknown status
Trial end date:
2021-07-25
Target enrollment:
Participant gender:
Summary
Anlotinib is a novel small molecule multi-target tyrosine kinase inhibitor that can inhibit
tumor angiogenesis and inhibit tumor cell growth. We performed second-generation gene
sequencing on pathological specimens and cerebrospinal fluid of patients with recurrent
glioblastoma.If patients have a genetic mutation （VEGFR，Kit，PDGFR，FGFR）and meet other
eligibility criteria, they will be treated with antroinib. The initial observation targets
were progression-free survival and adverse reactions. The secondary objective was overal
survival.